• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Traditional Chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors.传统中药及其成分可有效降低免疫检查点抑制剂介导的耐药性。
Front Immunol. 2024 Nov 26;15:1429483. doi: 10.3389/fimmu.2024.1429483. eCollection 2024.
2
Traditional Chinese medicine enhances the effectiveness of immune checkpoint inhibitors in tumor treatment: A mechanism discussion.中药增强免疫检查点抑制剂在肿瘤治疗中的疗效：机制探讨
J Ethnopharmacol. 2025 Feb 10;338(Pt 1):118955. doi: 10.1016/j.jep.2024.118955. Epub 2024 Oct 18.
3
Evaluation of efficacy, safety and underlying mechanism on Traditional Chinese medicine as synergistic agents for cancer immunotherapy: A preclinical systematic review and meta-analysis.中药作为癌症免疫治疗协同剂的疗效、安全性及潜在机制评估：一项临床前系统评价与荟萃分析
J Ethnopharmacol. 2025 Feb 10;338(Pt 1):119035. doi: 10.1016/j.jep.2024.119035. Epub 2024 Nov 5.
4
Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis.中药治疗免疫检查点抑制剂诱导的结肠炎的潜在作用机制
Front Immunol. 2024 Apr 10;15:1366489. doi: 10.3389/fimmu.2024.1366489. eCollection 2024.
5
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance.癌症免疫治疗耐药的机制、联合治疗及生物标志物。
Cell Commun Signal. 2024 Jun 19;22(1):338. doi: 10.1186/s12964-024-01711-w.
6
Emerging Strategies for Local Delivery of Immune Checkpoint Inhibitors to Potentiate Cancer Immunotherapy: Current Status and Future Prospects.新兴的免疫检查点抑制剂局部递送策略增强癌症免疫治疗：现状与未来展望。
ACS Appl Mater Interfaces. 2024 Nov 6;16(44):59682-59696. doi: 10.1021/acsami.4c12603. Epub 2024 Oct 22.
7
Unlocking the potential of pyroptosis in tumor immunotherapy: a new horizon in cancer treatment.解锁细胞焦亡在肿瘤免疫治疗中的潜力：癌症治疗的新领域。
Front Immunol. 2024 Jun 14;15:1381778. doi: 10.3389/fimmu.2024.1381778. eCollection 2024.
8
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.癌症治疗中使免疫检查点抑制剂致敏的当前趋势。
Mol Cancer. 2024 Dec 26;23(1):279. doi: 10.1186/s12943-024-02179-5.
9
Tumor-intrinsic kinase: A promising target for overcoming resistance to immune checkpoint blockade therapies.肿瘤内在激酶：克服免疫检查点阻断疗法耐药性的一个有前景的靶点。
Mol Ther. 2024 Oct 2;32(10):3209-3210. doi: 10.1016/j.ymthe.2024.09.013. Epub 2024 Sep 20.
10
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.调节肠道菌群以克服癌症免疫治疗中免疫检查点阻断的耐药性。
Curr Opin Pharmacol. 2020 Oct;54:1-10. doi: 10.1016/j.coph.2020.06.004. Epub 2020 Jun 30.

引用本文的文献

1
Traditional Chinese medicine in the prevention and treatment of lung cancer metastasis by regulating tumor-associated macrophages: a narrative review.传统中医通过调节肿瘤相关巨噬细胞预防和治疗肺癌转移：一项叙述性综述
Transl Lung Cancer Res. 2025 Jun 30;14(6):2281-2295. doi: 10.21037/tlcr-2025-380. Epub 2025 Jun 26.
2
Research progress and molecular mechanism of oridonin in the treatment of malignant melanoma.冬凌草甲素治疗恶性黑色素瘤的研究进展及分子机制
Front Oncol. 2025 Jun 17;15:1606325. doi: 10.3389/fonc.2025.1606325. eCollection 2025.

本文引用的文献

1
Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).与 PD-1/PD-L1 抑制剂相关的头颈部鳞状细胞癌（HNSCC）的心血管不良事件和免疫相关不良事件。
Sci Rep. 2024 Oct 29;14(1):25919. doi: 10.1038/s41598-024-75099-5.
2
Administration of rIL-33 Restores Altered mDC/pDC Ratio, MDSC Frequency, and Th-17/Treg Ratio during Experimental Cerebral Malaria.在实验性脑型疟疾期间，给予重组白细胞介素-33可恢复改变的髓样树突状细胞/浆细胞样树突状细胞比例、髓源性抑制细胞频率以及辅助性T细胞17/调节性T细胞比例。
Pathogens. 2024 Oct 8;13(10):877. doi: 10.3390/pathogens13100877.
3
Intermittent Fasting and Fasting-mimicking Diet: Promising Strategies in Cancer Management.间歇性禁食和模拟禁食饮食：癌症管理中有前景的策略。
Curr Med Chem. 2024 Oct 24. doi: 10.2174/0109298673332052241008060857.
4
Pyroptosis induced by natural products and their derivatives for cancer therapy.天然产物及其衍生物诱导的细胞焦亡在癌症治疗中的作用。
Biomater Sci. 2024 Nov 5;12(22):5656-5679. doi: 10.1039/d4bm01023j.
5
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.新辅助免疫疗法治疗错配修复缺陷型和微卫星稳定型结直肠癌：治疗策略和可能的反应生物标志物。
Nat Rev Clin Oncol. 2024 Dec;21(12):839-851. doi: 10.1038/s41571-024-00943-6. Epub 2024 Sep 24.
6
The effect of traditional Chinese medicine on psychological conditions among elderly patients with cancer: a scoping review.中医药对老年癌症患者心理状况的影响：系统评价。
Psychogeriatrics. 2024 Nov;24(6):1389-1401. doi: 10.1111/psyg.13182. Epub 2024 Aug 29.
7
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.免疫抑制剂对免疫检查点抑制剂相关免疫不良反应管理的影响。
Eur J Cancer. 2024 Jun;204:114065. doi: 10.1016/j.ejca.2024.114065. Epub 2024 Apr 14.
8
Artesunate attenuates the tumorigenesis of choroidal melanoma via inhibiting EFNA3 through Stat3/Akt signaling pathway.青蒿琥酯通过抑制 Stat3/Akt 信号通路抑制 EFNA3 从而抑制脉络膜黑色素瘤的发生。
J Cancer Res Clin Oncol. 2024 Apr 17;150(4):202. doi: 10.1007/s00432-024-05711-8.
9
Artesunate Alleviates Kidney Fibrosis in Type 1 Diabetes with Periodontitis Rats via Promoting Autophagy and Suppression of Inflammation.青蒿琥酯通过促进自噬和抑制炎症减轻 1 型糖尿病合并牙周炎大鼠的肾纤维化。
ACS Omega. 2024 Mar 29;9(14):16358-16373. doi: 10.1021/acsomega.4c00020. eCollection 2024 Apr 9.
10
Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.调节性 T 细胞作为癌症治疗中 PD-1/PD-L1 阻断后发生超进展性疾病的关键触发因素和潜在靶点。
Int Immunopharmacol. 2024 May 10;132:111934. doi: 10.1016/j.intimp.2024.111934. Epub 2024 Apr 3.

传统中药及其成分可有效降低免疫检查点抑制剂介导的耐药性。

Traditional Chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors.

作者信息

Guo Mingxin, Fang Wentong, Hu Zhiqiang

机构信息

Department of Pharmacy, The Affiliated Yixing Hospital of Jiangsu University, Yixing, China.

Department of pharmacy, Jiangsu Province Hospital, Nanjing, China.

出版信息

Front Immunol. 2024 Nov 26;15:1429483. doi: 10.3389/fimmu.2024.1429483. eCollection 2024.

DOI:10.3389/fimmu.2024.1429483
PMID:39660124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11628391/
Abstract

Immunotherapy has become a global focus in cancer treatment and research, with promising results from targeting immune checkpoints in tumors like non-small cell lung cancer, colon cancer, and melanoma. However, resistance to immune checkpoint inhibitors (ICIs) remains a significant challenge. Traditional Chinese medicine (TCM), known for its low toxicity and minimal side effects, shows promise in enhancing cancer treatment when combined with modern therapies. This study reviews recent research on ICIs resistance mechanisms and highlights TCM's potential in overcoming this resistance, aiming to improve ICIs efficacy while minimizing toxicity.

摘要

免疫疗法已成为癌症治疗和研究的全球焦点，在针对非小细胞肺癌、结肠癌和黑色素瘤等肿瘤中的免疫检查点方面取得了有前景的成果。然而，对免疫检查点抑制剂（ICI）的耐药性仍然是一个重大挑战。以低毒性和最小副作用著称的传统中药，在与现代疗法联合使用时，显示出增强癌症治疗效果的潜力。本研究回顾了最近关于ICI耐药机制的研究，并强调了中药在克服这种耐药性方面的潜力，旨在提高ICI的疗效，同时将毒性降至最低。